Glucagon in the treatment of Paget's disease of bone.
Glucagon given by intravenous infusion at a dosage of 0.2 to 0.8 mg/hour to four patients with Paget's disease of bone resulted in a dramatic fall in plasma alkaline phosphatase. This was associated with a fall in 24-hour urinary calcium and in total urinary hydroxyproline excretion and a marked relief of bone pain.GLUCAGON MAY INDUCE THESE CHANGES BY THREE POSSIBLE MECHANISMS: (1) by stimulating release of calcitonin; (2) by a direct action of the hormone on bone; and (3) by stimulation of certain bone pyrophosphatases, thus altering the local mechanisms controlling the rate of bone formation and resorption.
D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood; D001862:Bone Resorption / Q000517:prevention & control; D001842:Bone and Bones / Q000201:enzymology; D002113:Calcification, Physiologic; D002116:Calcitonin / Q000378:metabolism; D002118:Calcium / Q000652:urine; D005260:Female; D005934:Glucagon / Q000627:therapeutic use*; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D008297:Male; D008875:Middle Aged; D010001:Osteitis Deformans / Q000188:drug therapy*; D011755:Pyrophosphatases / Q000378:metabolism
D002116:Calcitonin; D005934:Glucagon; D000469:Alkaline Phosphatase; D011755:Pyrophosphatases; D006909:Hydroxyproline; D002118:Calcium